1.
Leuk Res
; 38(5): 594-600, 2014 May.
Article
in English
| MEDLINE
| ID: mdl-24661629
ABSTRACT
In vitro, Imatinib inhibits the proliferation and stimulates the osteogenic and adipogenic differentiation of mesenchymal stromal cells (MSC). However, it is unknown whether Imatinib affects the biology of MSC in vivo. We asked whether MSC from long-term Imatinib-treated CML patients were affected by the in vivo treatment. MSC from untreated and Imatinib-treated patients displayed normal functional properties (i.e. proliferation, immunophenotype, differentiation and hematopoietic supportive capacity) - but a decreased frequency. In vitro, Imatinib lost its effect when discontinued; which suggest that it has a reversible effect on MSC. Therefore it might lose its effect on MSC after discontinuation in vivo.
Subject(s)
Antineoplastic Agents/therapeutic use , Benzamides/therapeutic use , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Mesenchymal Stem Cells/physiology , Piperazines/therapeutic use , Pyrimidines/therapeutic use , Cell Differentiation , Fusion Proteins, bcr-abl/metabolism , Humans , Imatinib Mesylate , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Mesenchymal Stem Cells/cytology , Phenotype
2.
Hemoglobin
; 23(3): 295-7, 1999 Aug.
Article
in English
| MEDLINE
| ID: mdl-10490145